Nemolizumab in Children Under 12: The Open Eczema Question
A new report asks whether nemolizumab, the IL-31-targeting biologic, can fill the treatment gap for children under 12 with moderate-to-severe atopic dermatitis.
Topic
Biologics
Topic
Biologics
Nature asks whether a psoriasis cure is now within reach
Nature published a piece claiming a psoriasis cure could be "in touching distance" — a headline that reframes a chronic disease a…
Real-World Prospective Study Tracks Skin and Systemic Gains Across Psoriasis Biologics
A Nature-published prospective study tracks cutaneous and systemic improvements across different biologic therapies in a real-wor…
Rare Case: Psoriasis and Vitiligo in One Patient Expose Clashing Immunity
A rare case report documents psoriasis and vitiligo in one patient, exposing opposing immune pathways in the same skin — and a co…
Tildrakizumab Holds Its Effect for 52 Weeks in Japanese Psoriasis Patients
Tildrakizumab sustained its benefit over 52 weeks in Japanese psoriasis patients in real-world care, adding durability evidence f…
J&J Reports Sustained Response for Its Psoriasis Drug
Johnson & Johnson reports sustained response for its psoriasis drug, a durability claim that shifts the conversation from rapid c…
JAAD Publishes Framework to Make HS Lymphoma Risk Actionable
Published online 16 October 2026 in JAAD, Wang and Fan's paper aims to turn known lymphoma risk in hidradenitis suppurativa into…
International Cost Comparison Puts HS Biologics Under the Microscope
A new international comparison examines cost efficiency of biologic therapies for hidradenitis suppurativa, with direct implicati…
GLP-1 Agonists Enter the Conversation on Psoriatic Disease
GLP-1 agonists are reframing cardiometabolic risk management in psoriatic disease, giving dermatologists a direct tool against th…
Dupilumab Shows Durable Efficacy and Safety in Pediatric Atopic Dermatitis
Dupilumab maintained durable efficacy and consistent safety across pediatric age groups in atopic dermatitis, Physicians Weekly r…